Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00818480 · ClinicalTrials.gov registry record · Phase 2
An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155
A Phase 2 study of Prostate Cancer and Melanoma, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 3
- Study locations
NCT00818480: Completed Phase 2 study of Prostate Cancer and Melanoma, sponsored by Astellas Pharma.
NCT00818480 is a Phase 2 study of Prostate Cancer and Melanoma that has completed, run by Astellas Pharma. The registered enrollment target is 10 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower). The trial reports 3 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00818480, a Phase 2 study of Prostate Cancer and Melanoma, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 3
- Study locations
Study Summary
This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.
Conditions Studied
Interventions
- DRUG YM155
Study Locations (3)
Texas
- Institute for Drug Development - San Antonio
- South Texas Accelerated - San Antonio
Utah
- Huntsman Cancer Hospital - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2006-02 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT00818480 record still lists
NCT00818480 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which YM155 is the first listed.
NCT00818480 reports a single indexed study location in Texas, Utah.
Frequently Asked Questions
What is clinical trial NCT00818480 about?
NCT00818480 is a clinical study titled "An Extension Study Administering YM155 to Subjects Previously Enrolled in Another Protocol Administering YM155". This protocol is open to subjects previously enrolled in and who had completed a Phase I or Phase II study administering YM155. Subjects who are receiving benefit from treatment with YM155 are eligible after completing the previous study.
What is the current status of trial NCT00818480?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2006-02. Estimated completion is 2012-08.
What conditions does trial NCT00818480 study?
This clinical trial studies the following conditions: Prostate Cancer, Melanoma, Non-Hodgkin's Lymphoma.
What interventions are being tested in trial NCT00818480?
The interventions under investigation include: YM155 (DRUG).
Who is sponsoring clinical trial NCT00818480?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00818480 being conducted?
This trial has 3 study locations across Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00818480's enrollment target sits among peer trials
10 718th of 735 higher than 13 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
RECRUITING · Phase 2
-
Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer
RECRUITING · Phase 2
-
Post-prostatectomy Radiation Therapy--Moderate Versus Ultra-hypofractionated (Also Known as Stereotactic Body Radiation Therapy [SBRT])
RECRUITING · Phase 2
-
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
RECRUITING · Phase 2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
RECRUITING · Phase 2
-
High Intensity Focused Ultrasound in Prostate Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia